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KEY POINTS
 Mycosis fungoides and Se´zary syndrome subtypes of cutaneous T-cell lymphoma (CTCL) have a
variable clinical course, ranging from indolent disease that does not alter life expectancy to aggres-
sive, rapidly progressive disease.
 Goals of treatment, especially in patients with early-stage disease, are to induce remission with
agents that have a low toxicity profile. The systemic retinoids are an important component of the
treatment options for all stages of this disease because of the ease of administration and relatively
low toxicity profile.
 Bexarotene is the only systemic retinoid approved by the Food and Drug Administration specifically
for CTCL but does require additional medications to treat the associated hyperlipidemia and hypo-
thyroidism during the duration of bexarotene treatment.
 Combination treatment with retinoids and other agents with activity against mycosis fungoides/
Se´zary syndrome appear to be well tolerated and associated with high response rates in relapsed
or treatment refractory patients in small studies and series.INTRODUCTION
Retinoids are signaling molecules that are struc-
tural and functional derivatives of vitaminA (retinol).
The term collectively describes naturally occurring
retinol and its metabolites, as well as synthetic an-
alogs. Retinoid receptors are found ubiquitously in
virtually all organ systems, and they regulate impor-
tant functions in the body, including embryonic
development, vision, immune and neural function,
as well as cell proliferation, differentiation, and
apoptosis.1,2 These compounds exert their effects
through control of gene expression. In theDepartment of Dermatology, Perelman School of Med
Boulevard, Suite 330S, Philadelphia, PA 19104, USA
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“biologic response modifiers” (BRMs) in that they
are dissimilar to traditional cytotoxic chemo-
therapy, inducing response without immune sup-
pression, and often augmenting the immune
response.3–5 Although there have been a number
of clinical studies using retinoids for treatment of
breast, ovarian, renal, head and neck, melanoma,
and prostate cancers, they are most prominently
used in the treatment of hematologicmalignancies.
In the case of acute promyelocytic leukemia, reti-
noids in the form of all-trans retinoic acid are used
as first-line treatment to restore normal myeloidicine, University of Pennsylvania, 3400 Civic Center
erelman School of Medicine, University of Pennsylva-
PA 19104.
ublished by Elsevier Inc. This is an open access article
org/licenses/by-nc-nd/4.0/).
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Huen & Kim716differentiation to leukemic cells, inducing the for-
mation of mature granulocytes.6 In T-cell lym-
phoma cells, retinoids are thought to induce
apoptosis and DNA fragmentation in affected T
lymphocytes.7,8
Cutaneous T-cell lymphomas (CTCLs) are a het-
erogeneous group of uncommon primarily mature
T-helper lymphoproliferative disorders. The most
common form ismycosis fungoides (MF),which ac-
counts for approximately 60% of all cases.9 It typi-
cally displays indolent behavior, although disease
progression to higher stages or transformation to
large-cell lymphoma can occur. Se´zary syndrome
(SS) is a related subtype of CTCL presenting as er-
ythroderma, with a significant population of circu-
lating atypical T-lymphocytes and typically has a
more aggressive course than MF. Patients with
the earliest stages of MF do not have decreased
survival due to their disease, and skin-directed
therapy, such as phototherapy or topical medica-
tions, are the mainstays of treatment.10 Addition-
ally, treatment with BRMs, such as interferons or
retinoids, also are commonly used in these pa-
tients, although systemic treatment is generally
reserved for patients with MF who have failed local
or skin-directed therapy or have more extensive
disease.5,10 The anecdotal use of retinoids for
treatment of MF was first reported in the 1980s,
both as monotherapy or in combination with
chemotherapy.3,11,12 Currently, topical and sys-
temic retinoids are an integral part of the treatment
armamentarium for CTCL. This article focuses pri-
marily on systemic retinoids in MF and SS.Table 1
Human nuclear receptors and ligands
Receptor Ligand(s)
Retinoic acid receptor (RAR) a, b, g All-trans retino
acitretin
Retinoic X receptor (RXR) a, b, g 9-cis retinoic a
Thyroid hormone receptor (TR) Thyroid hormo
Vitamin D3 receptor (VDR) Vitamin D, cal
Peroxisome proliferator-activated
receptor (PPAR) a, b, g
Fatty acids, fib
Pregnane X receptor Xenobiotics
Liver X receptor a, b (LXR) Oxysterols
Estrogen receptor a, b Estradiol
Progesterone receptor Progesterone
Glucocorticoid receptor Cortisol, cortic
Mineralocorticoid receptor Aldosterone, s
Androgen receptor Testosterone
Data from Soko1owska-Wojdy1o M, qugowska-Umer H, Macie
neous T-cell lymphomas. Postepy Dermatol Alergol 2013;30:19RETINOIDS AND MECHANISM OF ACTION
All retinoids have similar molecular structure, con-
taining a benzene ring, a polyene chain, and a
carboxylic end group. In the body, retinol is metab-
olized to all-trans retinoic acid and then further
isomerizes to 13-cis retinoic acid (isotretinoin) and
9-cis retinoic acid in the liver.2 Subsequently, syn-
thetic retinoids have been derived from retinol,
including mono-aromatic second-generation reti-
noids (eg, etretinate, acitretin) followed by polyaro-
matic third-generation compounds called
arotenoids (eg, bexarotene).13More recently, alitre-
tinoin, which is a synthetic analog of 9-cis retinoic
acid, has been developed with efficacy in atopic
dermatitis and a few reports showing effects in
MF/SS.
Retinoids bind to 2 distinct families of nuclear re-
ceptors regulating gene transcription called
retinoic acid receptors (RARs) and retinoic X recep-
tors (RXRs). Each receptor is associated with 3
subtypes, a, b, and, g, which bind to specific li-
gands.1,14 These receptors are part of a larger su-
perfamily of nuclear receptors, including thyroid
hormone receptor, vitamin D3 receptor, and gluco-
corticoid receptor (Table 1).1 Transactivation of
some of these other nuclear receptors is believed
to be linked to some of the side effects seen with
the retinoids.1
Despite significant progress in elucidating the
mechanism by which retinoids exert their activity,
their effect on tumorigenesis and cancer biology
remains poorly understood. The RAR receptorsic acid, 9-cis retinoic acid, isotretinoin, etretinate,
cid, bexarotene
ne
citriol
rates, leukotriene B4, thiazolidinediones
osteroids
pironolactone
jewska-Radomska A. Oral retinoids and rexinoids in cuta-
–29.
Systemic Retinoids in Cutaneous T-cell Lymphoma 717bind only to all-trans retinoid acid, 9-cis retinoic
acid or synthetic isotretinoin, etretinate, and aci-
tretin. The RXR receptors exclusively bind to
9-cis retinoic acid or synthetic retinoids such as
bexarotene (which is often referred to as a rexi-
noid).3,15 These receptors can form homodimers
or heterodimers with each other or with other nu-
clear hormone receptors, such as thyroid hormone
receptor or liver X receptor. The RXR receptor also
can form a tetramer in its resting state. Once
bound to a ligand, the receptor induces a confor-
mation change forming a ligand-receptor com-
plex. These complexes bind directly to specific
DNA sequences called hormone response ele-
ments that affect transcription of specific genes
and production of specific peptides downstream,
which can induce and maintain terminal differenti-
ation of malignant cells.1,16 Fig. 1 is a diagram
demonstrating possible combinations of receptor
dimers formed by rexinoid receptors.
Retinoids also have been shown to inhibit orni-
thine decarboxylase activity, an enzyme that is up-
regulated in the presence of tumor-promoting
substances.17 It is believed that retinoids also1. 1. RXR homodimer
2. RXR permissive heterodimer
3. RXR non-permissive heterodimer
RXR Nuclear Receptor
DR elements Transcription
RXR RXR
DR elements Transcription
RXR
DR elements Transcription
Nuclear Receptor
* *
*
**
*= ligand
Fig. 1. Retinoid receptor responses. (1) RXR forms ho-
modimers with itself, and with ligand binding, leads
to activation of transcription. (2) RXR also forms
permissive heterodimers with other nuclear receptors,
such as PPAR and LXR-activation of transcription occurs
with binding of ligand to either receptor. (3) RXR forms
nonpermissive heterodimers with RAR, TR, or VDR.
Activation of transcription occurs only with ligand
binding on both receptors. DR elements, direct repeat
elements; TR, Thyroid hormone receptor; VDR, vitamin
D3 receptor. a Ligand.promote the production of gap junctions, which
are lost during malignant transformation, as well
as their glycoproteins, which aid in cell communi-
cation, adhesion, and growth.16
Rexinoids, such as bexarotene, bind exclusively
to the RXR, and its activation has been shown to
induce apoptosis involving activation of the cas-
pase pathway. Bexarotene has been shown to
activate caspase-3, a key executor of the
apoptotic pathway, with resultant apoptosis as evi-
denced by increased poly (ADP-Ribose) polymer-
ase and downregulation of survivin (a suppressor
of caspase-induced apoptosis).8 Retinoids reduce
expression of Bcl-2 protein and upregulate bax
proteins, which also are involved in apoptotic path-
ways.18 Activation of RXR receptor also has been
associatedwith activation of p53, a tumor suppres-
sor protein, by facilitating its binding to promoters
leading to cell cycle arrest.19 Other antitumor ef-
fects of rexinoids include reduction inmatrixmetal-
loproteinases, vascular endothelial growth factor,
and epidermal growth factor, which are important
factors in angiogenesis as well as tumor cell migra-
tion and invasion.20
Various investigators have reported the immuno-
modulatory effects of retinoids and rexinoids.
RARs are constitutively expressed in human T
and B lymphocytes. Activation of RAR g has been
shown to promote CD81 T-cell responses.15 Reti-
noids upregulate Langerhans cell antigen presen-
tation and surface expression of HLA-DR and
CD11c, which is important for T-cell activation.21
Retinoids and rexinoids also have been shown to
upregulate interleukin-2 receptor (IL-2R) expres-
sion with associated increase in interferon (IFN) g
levels.22 Gorgun and Foss4 reported elevation in
IL-2R levels in human T-cell and B-cell leukemia
cell lines after treatment with rexinoids. In the
same study, they reported the upregulation of IL-
2R in the malignant cells translated to increase
sensitivity to denileukin diftitox (a fusion protein of
diphtheria toxin bound to the ligand for the IL-2R
previously used in the treatment of CTCL).4,23RETINOIDS IN CUTANEOUS T-CELL
LYMPHOMA
Currently all systemic retinoids in use for CTCL are
oral agents (administered with food for optimal ab-
sorption). Isotretinoin was the first retinoid used for
the off-label treatment of CTCL. In 1983, Kessler
and colleagues11 first reported activity in 4 patients
with MF treated with isotretinoin at doses of 1 to
3 mg/kg per day with response seen in all patients,
1 patient with a complete response (CR). The
investigator proceeded to study 21 additional pa-
tients with plaque, tumor, and erythrodermic MF,
Huen & Kim718including 5 with SS using doses of 1 to 2mg/kg per
day.24 Forty-four percent of patients were reported
to have a clinical response, but most patients
required dosage adjustment because of mucocu-
taneous side effects.24 In 2005, Leverkus and col-
leagues25 reported effective treatment of
folliculotropic MF with isotretinoin at up to
1mg/kg per daywith specific regard tominiaturiza-
tion of cysts and comedones associated with this
subtype. This effect may be due to the strong affin-
ity of isotretinoin for the pilosebaceous unit. Higher
doses of isotretinoin (eg, >1 mg/kg per day) pro-
duced similar response rates with higher rates of
toxicity compared with 1 mg/kg per day.24 Overall,
use of isotretinoin in MF/SS resulted in clinical re-
sponses of 43% to 100%with CR rates of typically
less than 20%and short response duration ranging
from 3 to 15 months.3
Etretinate was the second retinoid approved for
clinical applications, originally approved for use in
psoriasis. It is highly lipophilic and has a signifi-
cantly longer half-life of more than 120 days
compared with 21 hours with isotretinoin and re-
quires 2 or more years to be completely eliminated
from the body after completion of treatment. As
such, it was replaced by its metabolite acitretin
with a shorter half-life of 2 to 4 days and an elimi-
nation period of approximately 2 months (though
alcohol ingestion can cause acitretin to convert
to etretinate and should be avoided during acitre-
tin use).26 Before the withdrawal of etretinate from
the market in 1998, several studies reported re-
sponses in patients with MF when used off-label.
Claudy and colleagues27 treated 12 patients with
etretinate monotherapy using 0.8 to 1.0 mg/kg
per day with response seen in all patients, but
only 1 patient achieved a CR. Clinical response
was seen in 55% of patients treated with etretinate
in a larger study of 29 patients reported by Molin
and colleagues28 with CR seen in only 1 patient.
The treatment response with etretinate appears
to be similar to that reported with isotretinoin.
Cheeley and colleagues29 reported a retrospec-
tive study on the use of acitretin in 32 patients with
MF/SS. There was a 59% overall response rate
with 1 patient achieving CR, but the interpretation
of these results may be confounded by other
concomitant treatments received by the patients.
Acitretin was used as monotherapy in only 6 pa-
tients with MF in the study, with clinical response
seen in approximately 25% of these patients.
The investigators in the retrospective review at-
tempted to compare response between acitretin
and bexarotene in patients treated with both med-
ications at different times in their treatment course,
but timing of use in the disease course and other
concomitant treatment may influence therapeuticoutcome, making comparison difficult. There is
limited experience with acitretin in MF (doses
used typically 10–50 mg daily), but anecdotal evi-
dence suggests that it may be less effective in
these patients than the other RAR agonists or bex-
arotene, but few comparative studies exist.1 All-
trans retinoic-acid has been shown in vitro to
have beneficial effects in CTCL and has also
been used off-label for CTCL.30,31
Bexarotene is a synthetic rexinoid with RXR se-
lective binding. Unlike its predecessor retinoids, it
was approved by the Food and Drug Administra-
tion (FDA) specifically for the treatment of CTCL
in 1999. Bexarotene was investigated in 2 phase
II-III trials in 58 patients with early-stage (I-IIA) MF
and in 94 patients with advanced-stage (IIB-IVB)
MF/SS.32,33 In the early-stage trial, patients were
treated at dosages ranging from 6.5, 300, and
650 mg/m2 per day, but the 300 mg/m2 per day
dosage was found to be the ideal starting dose
due to toxicity.3 Clinical responses in this study
were reportedly 20%, 54%, and 67% in the 6.5,
300, and 650 mg/m2 per day treatment groups,
respectively.32 Of the advanced-stage patients,
56 were treated at a dosage of 300 mg/m2 per
day and 38 at a dosage of more than 300 mg/m2
per day. Patients treated at 300 mg/m2 per day
had clinical responses in 45% (25 of 56) of patients
compared with 55% (21 of 38) of patients in the
higher-dose treatment group, suggesting that
there is a dose-related treatment response. The
CR rates for the 300 mg/m2 per day group was
2% compared with 13% in the higher-dose group.
The median time to response was 180 days and
time to progression was projected to be 299 days
for the lower-dose group and 385 days for the
higher-dose group. Among patients with a history
of previous retinoid therapywho had not previously
responded to other retinoids or had previously re-
sponded but progressed, a large portion (54%)
improvedwith bexarotene.More adverse reactions
were reported in the higher-dose group with
approximately13% of patients in this group dis-
continuing treatment because of side effects
compared with 7% in the lower-dose group.33
Another large retrospective trial was reported by
Abbott and colleagues34 in 66 patients with MF
and SS with most patients having advanced-
stage MF/SS (IIB-IVB). Patients were included if
they had received 150 to 300 mg/m2 daily within
the study period. Other treatment modalities,
such as radiation or extracorporeal photopheresis
(ECP), were used in some patients. Twenty-eight
patients completed at least 1 month of treatment
with bexarotene as monotherapy, and in these pa-
tients, 46% achieved a clinical response, with 14%
(4 patients) achieving a CR and 32% (9 patients)
Systemic Retinoids in Cutaneous T-cell Lymphoma 719achieving a partial response (PR). In patients
treated with bexarotene in combination with other
treatment modalities, the CR rate was 5% and
PR rate was 37%. Bexarotene appears to have
more potent activity in MF compared with its pre-
decessors, but not all patients respond to mono-
therapy and some fail to maintain remission,
prompting investigation into its use in combination
with other agents. Bexarotene is available as a
75-mg capsule.
Alitretinoin is another synthetically derived reti-
noid (9-cis retinoic acid), which can bind to both
RAR and RXR, hence its classification as a pan-
retinoic receptor agonist.1 It was approved in
1999 by the FDA for topical use in localized AIDS-
related Kaposi sarcoma and has been available in
Europe since 2008 as an oral formulation for the
treatment of refractory severe chronic hand
dermatitis.35,36 Oral alitretinoin has been used for
treatment of MF as reported in a case series of 2
patients, 1 with refractory disease, resulting in
PRs and no significant side effects.37 More
recently, a retrospective study described efficacy
of alitretinoin (10 or 30 mg daily) when combined
with other therapies (including topical steroids,
topical calcineurin inhibitors, phototherapy, IFN-
alpha, and/or photopheresis) in 10 patients with
MF (stages IA–IIB) and 1 patient with SS (4 CRs
and 6 PRs). Side effects were uncommon and
included headache, dyslipidemia, and low
thyroid-stimulating hormone (TSH) without other
thyroid abnormalities.38 This drug holds significant
promise for the treatment of MF/SS, but further
studies are needed to investigate its efficacy and
safety in this patient population.
Retinoids also have been studied in combination
with other treatment modalities (both skin directed
and other systemic agents) in MF/SS in an attempt
to improve response rates, prolong remission, and
decrease adverse effects by using lower doses
with nonoverlapping toxicities. Of note, the limita-
tion of these combination studies are that most of
them were not controlled, were without compar-
ator arm, had a limited number of patients, and
were performed before International Society
of Cutaneous Lymphomas (ISCL)/European
Organization for the Research and Treatment of
Cancer (EORTC) revisions in CTCL staging (2007)
and ISCL/EORTC/US Cutaneous Lymphoma
Consortium uniform response criteria definitions
(2010), thus making it difficult to accurately
compare response rates.39,40 Furthermore,
because of the paucity of data, it remains unclear
if combination therapies are definitively superior to
monotherapy.41
Systemic retinoids combined with skin-directed
therapy, such as phototherapy (ultraviolet B [UVB])or psoralen with ultraviolet A phototherapy (PUVA),
referred to as Re-UVB or Re-PUVA are well-known
combination therapies for many skin conditions
(psoriasis, eczema). In MF/SS, isotretinoin was
studied in combination with PUVA, with high
response rates in 66 patients, with CR in 72% of
patients. Although the clinical response was
similar to PUVA alone, the study found that fewer
UVA treatments were needed for response when
the combination was used.42 PUVA also was com-
bined with acitretin in 42 patients with CTCL, pro-
ducing a CR rate of 38%. This was significantly
lower compared with the comparator arm of
PUVA with IFN, which had a CR rate at 70%.43
Despite occasional association with photosensi-
tivity in the early clinical studies, since its FDA
approval in 1999, bexarotene has been combined
successfully with phototherapy in patients with
CTCL. In patients with MF stage IA-IIB, combina-
tion of low-dose bexarotene (75 mg per day) with
PUVA led to clinical response in all patients with
CR seen in 63% of patients.44 In a prospective
study of 14 patients with relapsed or treatment-
refractory MF (stage IA-III), patients were treated
with bexarotene at 150 to 300 mg per day concur-
rently with PUVA. Overall response rate was 67%,
with 29% CRs.45 In a large randomized controlled
trial comparing PUVA versus bexarotene plus
PUVA (EORTC 21011), 87 patients with stage IB/
IIA MF were randomized to each treatment group
but no significant difference in response rate
(71% PUVA vs 77% combination arm) or response
duration (9.7 PUVA vs 5.8 months combination)
was found.46
Bexarotene also has been combined with
narrow-band UVB (NBUVB) therapy in case re-
ports. One patient with stage IB plaque-stage MF
was treated successfully with low-dose bexaro-
tene (75 mg daily) and NBUVB treatment 3 times
weekly. The patient was previously treatment re-
fractory and NBUVB was used in place of PUVA
because of the history of multiple basal cell carci-
nomas.47 Another case report in a patient with
plaque-stage MF responded to a combination of
bexarotene 300 mg daily with NBUVB. The dis-
ease flared when either bexarotene or NBUVB
was discontinued, suggesting a possible synergis-
tic or additive effect.48
Combination trials using retinoids with other
systemics, such as IFNs, have been reported by
various investigators. This combination is attrac-
tive because of synergistic effects of retinoid stim-
ulation of Th1 activity through IL-12 production
and inhibition of Th2 response by IFN-alpha and
IFN-gamma.49 Isotretinoin at 1 mg/kg per day
was combined successfully with IFN-alfa-2b 2
million units (MU) 3 times weekly in 7 patients
Huen & Kim720with clinical objective response (OR) seen in 57%
of patients (29% achieving CR).50 Isotretinoin
also was studied in combination with IFN-alfa as
induction therapy together with total-body elec-
tron beam radiation and chemotherapy in 28 pa-
tients. Overall response in this study was 82%,
with 71% achieving CR.51 Isotretinoin at 1 mg/kg
per day has been investigated in combination
with 3 MU daily of IFN-alfa in 18 patients with
MF/SS.52 Patients in this study had advanced-
stage disease (IIB-IV) and were found to have OR
rates of 33% with half the responders having SS.
It appears that the combination was well tolerated.
Bexarotene has been investigated in a phase II
trial in combination with IFN-alfa in 22 patients
with MF/SS. Most of the patients in this study
had advanced-stage disease (with 86% of pa-
tients having stage II-IV disease). Patients were
treated initially with bexarotene 300 mg/m2 per
day alone for 8 weeks followed by the addition of
IFN-alfa-2b at 3 to 5 MU 3 times weekly for 8 addi-
tional weeks if CR was not achieved with bexaro-
tene alone. No patient achieved CR during the
first 8 weeks of treatment with bexarotene alone.
The overall response rate was 39%, with 1 patient
achieving CR. Of note, 4 additional responses
were observed with the addition IFN in the second
stage of the study, with 1 patient initially having PR
to bexarotene alone converting to CR.53
ECP is a treatment modality highly effective in
patients with SS with treatment responses as a
monotherapy reported at 60% and 19% CR.54
Bexarotene at dosages ranging from 225 to
750 mg per day or up to 300 mg/m2 daily in com-
bination with ECP led to high response rates of
75% to 80% in small studies.49,55 In another study
in patients with SS, bexarotene at 150 mg per day
was added, as part of a multimodality approach to
treatment, to monthly ECP, PUVA with and without
IFN-gamma or alfa 3 times weekly producing CRs
in 3 of 5 patients and PR in the other 2 patients.56
Retinoids and rexinoids also have been used in
combination with other biologic and chemothera-
peutic agents active against MF/SS. The combina-
tion of bexarotene in combination with denileukin
diftitox is believed to be synergistic, as retinoids
have the ability to enhance the expression of
high-affinity IL-2 receptor and thereby increase
the susceptibility to denileukin diftitox.4 This effect
was observed at bexarotene dosages of 150 mg
per day or higher. Fourteen patients with MF/SS
treated with the combination of bexarotene 75 to
375 mg per day and denileukin diftitox 18 mg/kg
per day 3 times every 21 days, had an overall
response rate of 67%, including 29% with a
CR.57 Bexarotene was studied in combination
with vorinostat, a histone deacetylase inhibitor, ina combination phase I/II study in 23 patients with
MF/SS in stages IB or higher. The maximum toler-
ated dosage in the phase I part of the study was
200 mg per day of vorinostat and 300 mg/m2 per
day of bexarotene. Patients in the phase II part
of the study were treated with 400 mg per day of
vorinostat and 150 mg/m2 per day of bexarotene.
Overall response was 26% (7% in phase I of the
study and 33% in phase II). This OR rate was
similar to patients treated with vorinostat mono-
therapy. However, improvement in pruritus was re-
ported in several patients. More than 20% of
patients required discontinuation from the trial
because of adverse effects, but adverse effects re-
ported (neutropenia, diarrhea, hypertriglyceride-
mia) did not appear to correlate with the higher
dosages used in the second phase of the study.58
Bexarotene also has been studied in MF/SS in
combination with chemotherapy agents, such as
methotrexate (MTX) and pralatrexate. In a retro-
spective study of 12 patients with MF (stage IA-
IIB) who were treated with bexarotene at dosages
of 75 to 300 mg per day and MTX at 5 to 30 mg
per week, overall response was 66% with 8%
achieving CR.59 Another study compared prala-
trexate with the combination of bexarotene at 150
to 300 mg/m2 daily and pralatrexate 15 mg/m2
weekly. Overall response was seen in 33% of pa-
tients treated with pralatrexate alone compared
with 50% in the combination group.60 Clinical re-
sponses with the combination appear to be higher
compared with the individual chemotherapy
agents alone. However, not all combination trials
demonstrate increased efficacy with the addition
of retinoids. In a recently published study evalu-
ating the combination of gemcitabine at
1000 mg/m2 intravenously on days 1 and 8 every
21 days with oral bexarotene at 300 mg/m2 per
day in 35 predominantly advanced-stage (IB-IVA)
CTCL, resulted in interruptionof the trialwhen lower
responses were revealed at interim analysis when
compared with single-agent gemcitabine.61 The
prominent studies involving the retinoids and rexi-
noid for treatment of MF/SS are listed in Table 2.
Resistance to retinoids has been reported in the
literature. In vitro evaluation of malignant T cells
found that malignant cells from as high as 33%
of patients with SS are intrinsically resistant to
bexarotene.62 The mechanism of bexarotene
resistance was investigated in a patient who
initially responded to treatment but later devel-
oped disease relapse. Malignant T cells obtained
from this patient at baseline underwent apoptosis
with exposure to bexarotene, but cells obtained
at relapse did not. No genetic coding alterations
in the RXR receptors were found to suggest that
mutation of the receptor was responsible for loss
Table 2
Notable studies of retinoids and rexinoids in CTCL
Treatment No. of Patients Stage of CTCL Dose Response Rate Author, Year
Isotretinoin 25 MF 20/SS 5 1–2 mg/kg/d OR 44%; CR12% Kessler
et al,24 1987
Isotretinoin 7 NA 100 mg/m2 daily OR 43%; CR 14% Warrell
et al,12 1983
Isotretinoin 15 MF 10/SS 5 0.2–2 mg/kg/d OR 59%; CR 21% Molin
et al,28 1987
Isotretinoin 20 MF 16/SS 4 1–2 mg/kg/d OR 80%; CR 33% Thomsen
et al,72 1984
Isotretinoin 6 MF 6/SS 1 1–2 mg/kg/d OR 100%; CR none Neely
et al,73 1987
Isotretinoin 1
interferon-alpha
7 MF 7 1 mg/kg/d (isotretinoin) 1
2 million units/d (interferon-
alpha-2b)
OR 57%; CR 29% Knobler
et al,50 1991
Isotretinoin 1
interferon-alpha
18 MF 12/SS 6 1 mg/kg/d (Isotretinoin) 1
3 million units/d (interferon-
alpha-2b)
OR 33%; CR 6% Tsimberidou
et al,52 2004
(continued on next page)
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Table 2
(continued )
Treatment No. of Patients Stage of CTCL Dose Response Rate Author, Year
Isotretinoin 1
interferon-alpha 1
TSEB/CT
28 MF 23/SS 5 1 mg/kg/d (isotretinoin) 1
5 million units/d (interferon-
alpha-2b) followed by TSEB/CT
OR 82%; CR 71% Duvic
et al,51 1996
Isotretinoin 1 PUVA 69 MF 69 1 mg/kg/d isotretinoin 1 PUVA CR 73% Thomsen
et al,42 1989
Etretinate 12 Parapsoriasis,
MF, SS
0.8–1 mg/kg/d OR 100%; CR 8% Claudy
et al,27 1983
Etretinate 29 MF/SS NA OR 55%; CR 21% Molin
et al,28 1987
Acitretin 32 (only 6 as
monotherapy)
MF 29/SS 2/
Unspecified 1
10–50 mg daily OR 25%; CR none
(monotherapy)
Cheeley
et al,29 2013
Bexarotene 94 MF 77/SS 17
Advanced stage
300 mg/m2/d and more than
300 mg/m2/d
OR 45%; CR 2% (300 mg/m2/d)
vs OR 55%; CR 13%
(>300 mg/m2/d)
Duvic
et al,33 2001
Bexarotene 58 MF 58 (early stage) 6.5, 300, 650 mg/m2/d OR 20%; CR none, OR 54%; CR
7%, and OR 67%; CR 27% in
the 6.5, 300, and 650 mg/m2/d
respectively
Duvic
et al,32 2001
Bexarotene 66 (only 28 as
monotherapy)
MF 25/SS 3 150–300 mg/m2/d OR 46%; CR 14% Abbott
et al,34 2009
Bexarotene 1
interferon-alpha
22 CTCL (IB-IV) 300 mg/m2/d (Bexarotene) 1
interferon-alpha-2b 3 million
units 3 times weekly
OR 39%; CR 6% Straus
et al,53 2007
Bexarotene 1 NBUVB 1 MF 1 (IB) 75 mg/d (Bexarotene) 1 NBUVB Improvement D’Acunto
et al,47 2010
Bexarotene 1 NBUVB 1 MF 1 (1B) 150, increased to 300 mg/d 1
NBUVB
Improvement Lokitz &
Wong,48 2007
Bexarotene 1 PUVA 14 MF 12/SS 2 150–300 mg/d (Bexarotene) 1
PUVA
OR 67%; CR 29% Papadavid
et al,45 2008
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Bexarotene 1 PUVA 8 MF 8 (IA-IB) 75 mg/d (Bexarotene) 1 PUVA OR 100%; CR 63% Singh & Lebwohl
et al,44 2004
Bexarotene 1 PUVA
vs PUVA
87 MF 87 (IB-IIA) Dosage not reported
(Bexarotene) 1 PUVA
OR 71%; CR 22.2% (PUVA)
vs OR 77%; CR 31.3%
(Combination)
Whittaker
et al,46 2012
Bexarotene 1
vorinostat
23 CTCL (stage IB
or higher)
150–300 mg/m2/d (Bexarotene) 1
200–400 mg/d vorinostat
OR 26%;(CR not reported) Dummer
et al,58 2012
Bexarotene 1 ECP 5 MF 3/SS 2 300 mg/m2/d (Bexarotene) 1
PUVA
OR 80%; CR 20% Tsirigotis
et al,55 2007
Bexarotene 1 ECP 8 MF/SS 100–300 mg/m2/d (Bexarotene) 1
ECP
OR 75%; CR 13% Talpur
et al,49 2002
Bexarotene 1
denileukin diftitox
14 CTCL (IA-IVB) 75–375 mg/d (Bexarotene) 1
18 mg/kg/d  3 d q21 d
OR 67%; CR 29% Foss et al,57 2005
Bexarotene 1
methotrexate
12 MF (Stage IA-IIB) 75–300 mg/d (Bexarotene) 1
methotrexate 5–30 mg/wk
OR 66%; CR 8% Kannangara
et al,59 2009
Bexarotene 1
gemcitabine
35 CTCL (IB-IVB) 300 mg/m2/d (bexarotene) 1
1000 mg/m2 D1&8 q21 d
(gemcitabine)
OR 31%; CR none Lower than
single agent gemcitabine
Illidge
et al,61 2013
Bexarotene 1
pralatrexate
14 MF 150–300 mg/m2/d (bexarotene) 1
15 mg/m2/wk (pralatrexate)
OR 50%; CR none Talpur
et al,60 2014
Alitretinoin 2 MF 2 30 mg/d OR/PR 100% Coors &
von den Driesch,37
2012
Alitretinoin 11 MF 10 (IA-IIB)/SS 1 10 or 30 mg daily OR 91%; CR 40% Kapser
et al,38 2015
Abbreviations: CR, complete response; CT, chemotherapy; CTCL, cutaneous T-cell lymphoma; MF, mycosis fungoides; NA, not available; NBUVB, narrow band UVB; OR, objective
response; PR, partial response; PUVA, psoralen plus UVA; SS, Se´zary syndrome; TSEB, total-body skin electron beam radiation.
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Table 4
Moderate to severe side effects of isotretinoin
Prevalence/Moderate/
Huen & Kim724of activity. A decline in the levels of RXR receptor
expression on cells, which is the receptor target
for bexarotene, was found as a possible
mechanism.63Side Effects Severe, %
Xerosis 36/20
Chelitis 28/0
Conjunctivitis 36/0
Fatigue 12/8
Arthralgia/Myalgia 8/8
Mental status change 8/0
Headache 8/0
Data from Kessler JF, Jones SE, Levine N, et al. Isotretinoin
and cutaneous helper t-cell lymphoma (mycosis fun-
goides). Arch Dermatol 1987;123:201–4.ADVERSE EFFECTS
Retinoids have a unique side-effect profile
compared with traditional cytotoxic agents. In clin-
ical studies of bexarotene, the most common
adverse effects are dyslipidemia, which has been
reported to occur in 100%of patients, and second-
ary hypothyroidism, reported in 40% to 100% of
patients taking bexarotene.1 Other common side
effects of bexarotene include liver function test ab-
normalities and dose-dependent leukopenia and
neutropenia, and rarely, gastrointestinal distur-
bances. Dyslipidemia also is common in patients
receiving isotretinoin. Table 3 is a list of common
side effects associated with bexarotene. In
contrast to the adverse effects seen in RXR ago-
nists, side effects associated with RAR agonists
seen in clinical studies in patients with CTCL
include xerosis (dose-limiting), cheilitis, head-
aches, and arthralgias/myalgias. See Table 4 for
side effects associated with isotretinoin. Because
of teratogenic effects, all retinoids and rexinoids
should be avoided in pregnant patients or in pa-
tients who wish to become pregnant.
Dyslipidemia is a dose-dependent and some-
times dose-limiting adverse reaction to both reti-
noids and rexinoids. This is typically manifested
as hypertriglyceridemia and less commonly hyper-
cholesterolemia. Activation of RAR leads to secre-
tion and decreased catabolism of triglyceride
particles leading to hypertriglyceridemia and re-
sulting decrease in high-density lipopoprotein.64
The binding of agonists to RXR has been shown
to result in increased apoCIII synthesis, a hepatic
protein that binds to lipids in the plasma and aids
in hepatic uptake of triglyceride particles. It alsoTable 3
Side effects of bexarotene
Side Effect
Central hypothyroidism
Hypertriglyceridemia
Dyslipidemia (increased low-density lipoprotein; decr
Liver toxicity
Headache
Skin rash, phototoxicity
Leucopenia
Adapted from Graeppi-Dulac J, Vlaeminck-Guillem V, Perier-M
the impact of retinoids on the thyroid axis. Eur J Endocrinol 2decreases lipoprotein lipase activity, which hydro-
lyzes triglycerides into fatty acids.65 Peroxisome
proliferator–activated receptors (PPARs) are
nuclear hormone receptors that are part of the
superfamily of receptors that also includes
retinoid receptors and others. These receptors
are strongly expressed in the skin and sebaceous
glands and are involved in oxidative pathways for
fatty acids.65 Retinoic X receptors form hetero-
dimers with PPARs and transactivation by rexi-
noids are believed to influence lipid metabolism.1
Triglyceride elevation also is regulated by transac-
tivation of LXR (Liver X receptor)/RXRheterodimers
by sterol regulatory element–binding proteins,
which are transcription regulators involved in
cholesterol biosynthesis.1 The LXR acts by control-
ling cholesterol metabolism in the liver as well as
reverse cholesterol transport from the peripheral
tissues to the liver by increasing plasma lipids. Acti-
vation of LXR onRXR heterodimersmay play only a
small part in the complex pathway of the influence
retinoids have onmetabolism of not only lipids, but
also of glucose and fatty acids.1 In patientsPrevalence, %
29–100
82–100
eased high-density lipoprotein) 30
11–20
16–20
8–13
6–11
uzet M, et al. Endocrine side-effects of anti-cancer drugs:
014;170:R256.
Systemic Retinoids in Cutaneous T-cell Lymphoma 725receiving bexarotene as monotherapy at
300 mg/m2 daily, hypertriglyceridemia was found
in 83%of patients, with 2 of 70 patients developing
pancreatitis due to themarkedly elevated triglycer-
ide levels.49 Of interest, it was reported by Talpur
and colleagues49 in 2002 that higher response
rates to bexarotene were associated with use of
lipid-lowering agents, with the highest response
rates seen in patients treated with atorvastatin
and fenofibrate. The higher response rate in these
patients may be merely a reflection of the higher
doses of bexarotene used (as dyslipidemia is a
dose-dependent phenomenon) or perhaps higher
sensitivity to bexarotene, which parallels dose
response. In contrast, patients who were treated
with the lipid-lowering agent gemfibrozil had more
severe hypertriglyceridemia and elevated bexaro-
tene serum levels. Its use is contraindicated with
bexarotene because it inhibits the oxidative meta-
bolism of the drug, thereby increasing toxicity.49
In one case series of 102 subjects on isotretinoin,
patients with predisposing conditions, such as
truncal obesity, hyperinsulinemia, or family history
of hypertriglyceridemia, were more likely to
develop retinoid-induced hypertriglyceridemia.66
Patients receiving either isotretinoin or bexarotene
should have baseline lipid evaluation before start-
ing therapy and closemonitoring should take place
during treatment. Inmost patients treatedwith bex-
arotene, treatment with lipid-lowering agents and
adherence to low-fat and low-cholesterol diet are
recommended at the onset of treatment.
Central hypothyroidism also is commonly
encountered in patients treated with bexarotene.
This is caused by suppression of the pituitary pro-
duction of the TSH. RXRg is the subtype of recep-
tor implicated in rexinoid-induced hypothyroidism
and is strongly expressed in the pituitary. In
contrast, isotretinoin and acitretin, RAR agonists,
do not have effects on TSH levels and hypothy-
roidism.2 Alitretinoin affects both RAR and RXR re-
ceptors, so it also may have effects on the thyroid
hormone axis. Similar to retinoid-induced hyperlip-
idemia, bexarotene-induced hypothyroidism also
appears to be dose dependent and reversible. In
patients with normal thyroid function before start-
ing treatment with bexarotene, serum TSH returns
to normal in most patients as early as 8 days after
stopping bexarotene.67 Because bexarotene pa-
tients typically require doses higher than replace-
ment thyroid doses used in hypothyroidism from
other causes, it has been suggested that an in-
crease in metabolism of thyroid hormone also
may play a role, perhaps through induction of liver
metabolic oxidative enzymes by retinoids.2,68 Pa-
tients should be started on empiric thyroid supple-
mentation at onset of treatment with bexarotene(25–50 mg daily) and increased based on monthly
serum-free thyroxine (free T4) levels. TSH remains
suppressed while on bexarotene, even with
adequate levothyroxine supplementation so the
TSH should not be used as the basis by which
one adjusts levothyroxine dose.
Dose-dependent leukopenia and neutropenia
can be observed in 10% of patients, but in
contrast to neutropenia observed after cytotoxic
chemotherapy, bexarotene neutropenia is not
typically associated with increased opportunistic
infections because neutrophils are functionally
normal. Given this, in our patients with MF/SS
who have no previous history of cytotoxic chemo-
therapy, we do not dose reduce bexarotene unless
absolute neutrophil count is less than 500/mL (Ellen
Kim, personal communication, 2015).
Alitretinoin has been associated with a lower
incidence of dyslipidemia and/or suppression of
the thyroid axis as compared with isotretinoin or
bexarotene, usually not requiring treatment for
these side effects.35 The mechanism explaining
this difference in side-effect profile is not known.37
No definitive guidelines exist for monitoring or
management of adverse effects associated with
retinoids and rexinoids. Isotretinoin is contraindi-
cated in patients who are pregnant and should be
used with caution in patients who have history of
uncontrolled psychiatric illness, inflammatory
bowel disease, and osteoporosis. Patients who
are being treated with isotretinoin in the United
States should follow monitoring as per the
iPLEDGE (a mandatory distribution program for
isotretinoin in the United States) program. This in-
cludes pregnancy monitoring for female patients
with childbearing potential at baseline and
monthly. Patients receiving isotretinoin should
avoid concomitant use of tetracycline class of anti-
biotics due to the increased risk of pseudotumor
cerebri. We also recommend baseline laboratory
testing such as complete blood count, liver func-
tion tests, and lipid profile while on therapy. Acitre-
tin and bexarotene are also contraindicated in
pregnancy and should be used with caution in pa-
tients with liver disease, history of alcohol abuse, or
uncontrolled hyperlipidemia. Female patients
should avoidbecomingpregnant for at least 3 years
after discontinuation of the acitretin. This should be
considered before initiation of treatment in any fe-
male patient who is of childbearing age. Use of
alcohol during treatment with acitretin results in
conversion of acitretin to etretinate and can result
in prolonged elimination of the retinoid.69
In patients on treatment with bexarotene, addi-
tional monitoring of free thyroxine (free-T4) levels
and not TSH is required (TSH is typically sup-
pressed in central hypothyroidism and is not
Plan to start Retinoids or Rexinoids
Baseline Screening and Laboratory Tests
1) Review patient’s medical history for risk factors predisposing to medication 
toxicity (history of metabolic syndrome, diabetes mellitis, history of thyroid 
disorder, etc) 
2) Review lifestyle modifications
-limit alcohol intake
-low-fat diet
-exercise
3) Laboratory Tests:
-Pregnancy (if applicable)
-Complete blood count
-Liver function tests
-Lipid panel
-Thyroid stimulating hormone/free Thyroxine (Bexarotene only)
For Patients starting on Bexarotene
Initiate empiric levothyroxine 25–50 μg/d
Initiate empiric statins (or HMG-CoA reductase inhibitors) (e.g. atorvastatin 40
mg/d) or 145 mg/d of fenofibrate, ideally at least 1 week prior to treatment
Fish oil supplementation or omega-3-acid etyl ester (Lovaza®)
Subsequent Screening and Laboratory Tests
1) Review potential adverse effects (isotretinoin: xerosis, mood change, joint 
pain, and headache; bexarotene: fatigue, headache, etc)
2) Laboratory Tests (monthly):
-Pregnancy (if applicable for isotretinoin)
-Complete blood count
-Liver function tests
-Lipid panel (fasting)
-Free thyroxine (not TSH) (Bexarotene only)
Hypertriglyceridemia
-add fenofibrate (not gemfibrozil) if not 
already on it or consider dose reduction if 
level >400 mg/dL 
-reinforce lifestyle modifications
Hypothyroidism
-increase levothyroxine dose by 
25 μg/d
Neutropenia
-hold therapy if <400–500/μL
Elevated liver enzymes
-hold therapy if >2X upper limit of normal
(can be delayed reaction)
Fig. 2. Recommendations for monitoring patients on systemic retinoids.
Huen & Kim726reliable as a measure of thyroid function in patients
on the medication). Bexarotene should not be
given in combination with gemfibrozil because of
increases in plasma concentration of bexarotene.
It is metabolized in the liver via cytochrome
p-450 3A4 and when used in combination with
3A4 inhibitors, such as azole class of antifungal
agents (ketoconazole, itraconazole) or grapefruit
juice or with 3A4 inducers, such as rifampin or
phenytoin, alterations in plasma levels of the
drug may occur.70 In all patients receivingretinoids, lifestyle modifications, including exer-
cise and dietary changes that include low-fat diet
and limits on alcohol consumption should be
advised. Recommended monitoring and manage-
ment of adverse effects for patients on retinoids
and rexinoids are shown in Fig. 2.71SUMMARY
MF and SS subtypes of CTCL have a variable clin-
ical course ranging from indolent disease that
Systemic Retinoids in Cutaneous T-cell Lymphoma 727does not alter life expectancy to aggressive, rapidly
progressive disease. Goals of treatment especially
in patients with early-stage disease are to induce
remission with agents that have a low toxicity pro-
file. Thesystemic retinoids are an important compo-
nent of the treatment options for all stages of this
disease because of the ease of administration and
relative low toxicity profile. Side effects appear to
be dose related and should be monitored closely
with hyperlipidemia observed with all retinoids,
whereas other side effects aremore drug or retinoid
class specific. For example, central hypothyroidism
appears to be limited to RXR agonists andmucocu-
taneousdryness toRARagonists. Bexarotene is the
only FDA-approved systemic retinoid approved
specifically for CTCL but does require additional
medications to treat the associated hyperlipidemia
and hypothyroidism during the duration of bexaro-
tene treatment. Combination treatment with reti-
noids and other agents with activity against MF/
SS appear to be well tolerated and associated
with high response rates in relapsed or treatment-
refractory patients in small studies and series.
Further high-quality clinical trials are needed in
MF/SS patients to confirm whether combination
therapies are superior to monotherapy.REFERENCES
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